Jan Oscarsson

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Positron Emission Tomography

Top Venues

Diabetes, obesity & metabolism

Therapeutic innovation & regulatory science

This page only lists publications with an associated author ORCID identifier.

Publications

Aino Latva-Rasku, Eleni Rebelos, Jouni Tuisku, Richard Aarnio, Achol A Bhowmik, Helmi Keskinen, Sanna Laurila, Minna Lahesmaa-Hatting, Laura Pekkarinen, Henrik Isackson, Anna Kaarina Kirjavainen, Jukka Koffert, Kerstin Heurling, Lauri Nummenmaa, Eleuterio Ferrannini, Jonas Oldgren, Jan Oscarsson, Pirjo Nuutila
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study. Diabetes care (2024)
Aino Latva-Rasku, Eleni Rebelos, Jouni Tuisku, Richard Aarnio, Achol A Bhowmik, Helmi Keskinen, Sanna Laurila, Minna Lahesmaa-Hatting, Laura Pekkarinen, Henrik Isackson, Anna Kaarina Kirjavainen, Jukka Koffert, Kerstin Heurling, Lauri Nummenmaa, Eleuterio Ferrannini, Jonas Oldgren, Jan Oscarsson, Pirjo Nuutila
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study. Diabetes care 47 (9) (2024)
Samvel B Gasparyan, Joan Buenconsejo, Elaine Kearney Kowalewski, Jan Oscarsson, Olof F Bengtsson, Russell Esterline, Gary G Koch, Otavio Berwanger, Mikhail N Kosiborod
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial. Therapeutic innovation & regulatory science 56 (5) (2022)
Jonas Oldgren, Sanna Laurila, Axel Åkerblom, Aino Latva-Rasku, Eleni Rebelos, Henrik Isackson, Maria Saarenhovi, Olof Eriksson, Kerstin Heurling, Edvin Johansson, Ulrica Wilderäng, Cecilia Karlsson, Russell Esterline, Eleuterio Ferrannini, Jan Oscarsson, Pirjo Nuutila
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study. Diabetes, obesity & metabolism 23 (7) (2021)